Argus
•
May 27, 2026
TGTX: Raising target price to $44.00
Summary
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercial
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: AbbVie Inc.
May 28, 2026
•
ABBV
The Argus Sustainable Growth Theme Model Portfolio
May 28, 2026
•
TT, DE, GOOGL, NDAQ, AAPL, AVGO, ADI, JPM, MRK, JNJ, TXN, MSFT, TFC, GLW, MA, LLY, TRV, SPGI, GE, NVDA, NOC, KO, KMI, AEP, GS, ECL, TMUS, ETN, AMZN, WMT
ARWR: Raising target price to $83.00
May 27, 2026
•
ARWR
SRPT: What does Argus have to say about SRPT?
May 27, 2026
•
SRPT
HALO: What does Argus have to say about HALO?
May 27, 2026
•
HALO
